Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A Worldwide Meta- and Mega-Analysis

Premika S.W. Boedhoe, M.Sc., Lianne Schmaal, Ph.D., Yoshinari Abe, M.D., Stephanie H. Ameis, M.D., Paul D. Arnold, M.D., Ph.D., Marcelo C. Batistuzzo, Ph.D., Francesco Benedetti, M.D., Jan C. Beucke, Ph.D., Irene Bollettini, Psy.D., Anushree Bose, M.A., Silvia Brem, Ph.D., Anna Calvo, M.Sc., Yuqi Cheng, Ph.D., Kang Ik K. Cho, B.Sc., Sara Dallaspezia, M.D., Damiaan Denys, M.D., Ph.D., Kate D. Fitzgerald, M.D., Jean-Paul Fouche, M.Sc., Mónica Giménez, Ph.D., Patricia Gruner, Ph.D., Gregory L. Hanna, M.D., Derrek P. Hibar, Ph.D., Marcelo Q. Hoexter, M.D., Ph.D., Hao Hu, M.D., Ph.D., Chaim Huyser, M.D., Ph.D., Keisuke Ikari, M.D., Neda Jahanshad, Ph.D., Norbert Kathmann, Ph.D., Christian Kaufmann, Ph.D., Kathrin Koch, Ph.D., Jun Soo Kwon, M.D., Ph.D., Luisa Lazaro, M.D., Ph.D., Yanni Liu, Ph.D., Christine Lochner, Ph.D., Rachel Marsh, Ph.D., Ignacio Martínez-Zalacain, M.Sc., David Mataix-Cols, Ph.D., José M. Menchón, M.D., Ph.D., Luciano Minuzzii, M.D., Ph.D., Takashi Nakamae, M.D., Ph.D., Christopher Pittenger, M.D., Ph.D., Y.C. Janardhan Reddy, M.D., Joao R. Sato, Ph.D., H. Blair Simpson, M.D., Ph.D., Noam Soreni, M.D., Carles Soriano-Mas, Ph.D., Gianfranco Spalletta, M.D., Ph.D., Michael C. Stevens, Ph.D., Philip R. Szeszko, Ph.D., David F. Tolin, Ph.D., Ganesan Venkatasubramanian, M.D., Ph.D., Susanne Walitza, M.D., M.Sc., Zhen Wang, M.D., Ph.D., Guido A. van Wingen, Ph.D., Jian Xu, Ph.D., Xiufeng Xu, M.D., Je-Yeon Yun, M.D., Ph.D., Qing Zhao, M.D., ENIGMA OCD Working Group, Paul M. Thompson, Ph.D., Dan J. Stein, M.D., Ph.D., Odile A. van den Heuvel, M.D., Ph.D.

Objective: Structural brain imaging studies in obsessive-compulsive disorder (OCD) have produced inconsistent findings. This may be partially due to limited statistical power from relatively small samples and clinical heterogeneity related to variation in illness profile and developmental stage. To address these limitations, the authors conducted meta- and mega-analyses of data from OCD sites worldwide.

Method: T1 images from 1,830 OCD patients and 1,759 control subjects were analyzed, using coordinated and standardized processing, to identify subcortical brain volumes that differ between OCD patients and healthy subjects. The authors performed a meta-analysis on the mean of the left and right hemisphere measures of each subcortical structure, and they performed a mega-analysis by pooling these volumetric measurements from each site. The authors additionally examined potential modulating effects of clinical characteristics on morphological differences in OCD patients.

Results: The meta-analysis indicated that adult patients had significantly smaller hippocampal volumes (Cohen’s $d=-0.13; \% \text{difference}=-2.80$) and larger pallidum volumes ($d=0.16; \% \text{difference}=3.16$) compared with adult controls. Both effects were stronger in medicated patients compared with controls ($d=-0.29, \% \text{difference}=-4.18$, and $d=0.29, \% \text{difference}=4.38$, respectively). Unmedicated pediatric patients had significantly larger thalamic volumes ($d=0.38, \% \text{difference}=3.08$) compared with pediatric controls. None of these findings were mediated by sample characteristics, such as mean age or scanning field strength. The mega-analysis yielded similar results.

Conclusions: The results indicate different patterns of subcortical abnormalities in pediatric and adult OCD patients. The pallidum and hippocampus seem to be of importance in adult OCD, whereas the thalamus seems to be key in pediatric OCD. These findings highlight the potential importance of neurodevelopmental alterations in OCD and suggest that further research on neuropaclity in OCD may be useful.

Am J Psychiatry 2016; 00:1–10; doi: 10.1176/appi.ajp.2016.16020201

Obsessive-compulsive disorder (OCD) is a neurodevelopmental disorder that affects 1%–3% of the population (1, 2). In more than half of OCD cases, symptoms emerge during childhood or adolescence (1, 3), and in more than 40% of these cases, the disorder persists into adulthood (4). OCD symptoms have been associated with structural and functional brain abnormalities in the parallel cortico-striato-thalamo-cortical circuits and other related brain networks, involving fronto-parietal, fronto-limbic, and cerebellar regions (5, 6).

Several studies have shown volumetric abnormalities in different deep gray matter structures, mainly the basal ganglia (7–10). Meta-analyses have repeatedly, although not consistently, reported larger volumes in the lenticular
nucleus extending to the caudate (11–14). In addition, Pujol et al. (7) showed that the relative enlargement of striatal areas in OCD patients was driven by higher age and longer illness duration, suggesting that basal ganglia alterations progress throughout the illness course, which is supported by the mega-analysis from the OCD Brain Imaging Consortium (15). These findings led to the hypothesis that preservation of basal ganglia volume resulted from neuroplastic changes due to chronic compulsivity.

Although these findings suggest ongoing neuroplasticity, a lifespan approach has seldom been used to understand the variation in structural abnormalities in OCD (5). Studying the brain characteristics of illness during childhood may minimize the potentially confounding effects of neuroplastic changes associated with chronic symptoms and long-term treatment. Pediatric studies have been sparse and small, leaving the extant findings inconclusive and variable. For example, some studies reported increased thalamus volume in adult (16, 17) and pediatric OCD patients (18), a finding supported by two meta-analyses (14, 19) showing larger thalamus volumes in OCD patients when pediatric and adult data were combined. In contrast, several recent meta-analyses showed no differences in thalamus volumes when adult and pediatric subjects were combined (11–13). The variation across studies may partially be explained by variations in the developmental and illness stages of the subjects included.

In view of the clinical heterogeneity of OCD, relatively small samples and differences in data acquisition, data processing protocols, and statistical analyses further contribute to the inconsistent findings. Different segmentation algorithms may produce variable estimates of subcortical volumes and therefore may influence their sensitivity to detect regionalized group differences (20). To overcome the heterogeneity in image processing and to increase sample sizes, especially pediatric samples, we initiated the OCD Working Group within the Enhancing NeuroImaging Genetics Through Meta-Analysis (ENIGMA) consortium (21).

The ENIGMA OCD Working Group is an international collaboration. Its current aim is to identify subcortical imaging markers that differ in OCD patients and healthy subjects, both in children and in adults. Therefore, we conducted meta- and mega-analyses on structural MRI data from 1,830 OCD patients and 1,759 healthy control subjects. The mega-analysis ensures information preservation and enables the examination of specific effects of demographic and clinical parameters. By employing meta- and mega-analysis, we sought to investigate whether the mega-analytic design has greater sensitivity to detect more subtle brain abnormalities from increased statistical power.

In this study, we investigated nine regions of interest (seven subcortical gray matter regions, the lateral ventricle, and total intracranial volume) in OCD patients compared with healthy control subjects by performing the largest meta- and mega-analyses to date. In additional exploratory analyses, we examined potential modulating effects of demographic, clinical, and methodological characteristics on subcortical brain volume in OCD. Based on previous meta- and mega-analyses, we expected subcortical brain volumes to vary across developmental stage, showing differences between pediatric and adult OCD, and across illness profile and stage, including comorbidity.

**METHOD**

**Samples**
The ENIGMA OCD Working Group includes 35 data sets from 25 international research institutes, with neuroimaging and clinical data from OCD patients and healthy control subjects, including both children and adults. We considered subjects age 18 and older as adults and those under age 18 as children. Because the literature has suggested differential effects between pediatric and adult samples, we performed separate meta- and mega-analyses for adult and pediatric data. The demographic and clinical characteristics of the participants at each center are summarized in Tables 1 and 2. In total, we analyzed data from 3,589 subjects, including 1,830 OCD patients (335 children and 1,495 adults) and 1,759 control subjects (287 children and 1,472 adults). All local institutional review boards permitted the use of extracted measures of the completely anonymized data.

**Image Acquisition and Processing**
Structural T1-weighted MRI brain scans were acquired and analyzed locally. Images were acquired at different field strengths (1.5-T and 3-T). The acquisition parameters of each sample are listed in Table S1 in the data supplement that accompanies the online edition of this article. The images were analyzed using the fully automated and validated segmentation program FreeSurfer, version 5.3 (22), following standardized protocols to harmonize analysis and quality control processes across multiple sites (see http://enigma.ini.usc.edu/protocols/imaging-protocols/). Segmentation of nine regions of interest, including seven subcortical gray matter structures (nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus), the lateral ventricle volumes (mean bilateral volume and right and left volumes separately), and total intracranial volume, were visually inspected for accuracy (see the Supplementary Methods section in the online data supplement).

**Meta-Analysis of Subcortical Brain Volumes**
We examined differences between OCD patients and controls across samples by performing a meta-analysis on the mean of the left and right hemisphere measures of each subcortical structure. The meta-analysis was based on multiple linear regression models, with the mean subcortical brain volume as the outcome measure and a binary indicator of diagnosis (0=controls, 1=patients) as the predictor of interest. All models were controlled for age, sex, and intracranial volume. Effect size estimates, adjusted for age, sex, and intracranial volume, were calculated using Cohen’s d, computed from.
the t statistic of the diagnosis indicator variable from the regression models.

To explore the influence of sex and age on between-group subcortical volume differences, we assessed the significance of diagnosis-by-sex and diagnosis-by-age interaction effects within each sample. Multiple linear regression models were used to investigate the within-group effects of age at onset, illness duration, illness severity (using the total severity score from the Yale-Brown Obsessive Compulsive Scale [YBOCS] and the Children’s YBOCS [23, 24]) as continuous variables.

To further study the neurodevelopmental aspects of illness within the adult samples, we performed separate stratified meta-analyses comparing early-onset OCD patients (onset before age 18) to controls, and late-onset OCD patients (onset at age 18 or older) to controls. Stratified meta-analyses were also performed for medicated and unmedicated patients. Likewise, separate stratified analyses were performed to investigate comorbid major depressive disorder, comorbid anxiety disorders, and OCD symptom dimensions (using the YBOCS symptom checklist; see Supplementary Methods in the data supplement).

All regression models and effect size estimates were fitted at each site separately. Subsequently, a final Cohen’s d estimate was obtained using an inverse variance-weighted random-effect meta-analysis model with the R package metafor, version 1.9-18. The meta-analysis of illness severity, age at onset, and illness duration were exceptions. The scores on these variables were considered as continuous variables, so effect sizes are reported using Pearson’s r, a partial correlation after removing nuisance variables (age, sex, and...
in intracranial volume). The final meta-analyzed Pearson's r was estimated following the same inverse variance-weighted random-effect meta-analysis models used for the other meta-analyses (see Supplementary Methods in the data supplement).

**Moderator Analyses**

Meta-regressions were performed to examine the effects of moderator variables on meta-analysis effect sizes. We tested whether hypothesized moderating factors, such as the mean age of each sample, scanner field strength, percentage of patients taking antidepressants, and percentage of patients taking antipsychotics, influenced the effect size estimates of the comparison of OCD patients with controls on all subcortical volumes across samples included in the meta-analysis. Each moderator variable was separately included as a fixed-effect predictor in a meta-regression model. We report uncorrected p values with a significance threshold determined by Bonferroni correction for testing nine regions of interest (p=0.05/9=5.6×10⁻³).

**Power Analysis**

Sample sizes that achieve 80% power to detect group differences given the presented effect sizes were calculated based on two-sided t tests assuming unequal variance, with G*Power, version 3.2.1 (25). See Supplementary Methods in the data supplement for full details of the power analysis.

**Mega-Analysis of Subcortical Brain Volumes**

We also performed a mega-analysis by pooling all volumetric measurements. The mega-analysis of each mean ([left+right]/2) subcortical volume was performed using the following model: Brain volume=βitateXage+βsexXsex+βintranuclear volumeXintranuclear volume+βdiagnosisXdiagnosis+βcohort1Xcohort1+...+βcohort35Xcohort35+ε. Similar to the meta-analysis, several covariates of interest were

---

**TABLE 2. Breakdown, by Site, of Clinical Characteristics of Patients With Obsessive-Compulsive Disorder (OCD) in the ENIGMA OCD Working Group Samples**

<table>
<thead>
<tr>
<th>Study Principal Investigator</th>
<th>Site</th>
<th>Medicated (%)</th>
<th>YBOCS(^a) Score Mean</th>
<th>YBOCS(^a) Score SD</th>
<th>Age at Onset (years) Mean</th>
<th>Age at Onset (years) SD</th>
<th>Lifetime Comorbid Disorders Anxiety (%)</th>
<th>Lifetime Comorbid Disorders Depression (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adult samples</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benedetti</td>
<td>Milan</td>
<td>64</td>
<td>30.9</td>
<td>5.6</td>
<td>16.0</td>
<td>6.1</td>
<td>1.5</td>
<td>10.6</td>
</tr>
<tr>
<td>Beucke</td>
<td>Berlin</td>
<td>40</td>
<td>20.1</td>
<td>7.1</td>
<td>17.2</td>
<td>7.8</td>
<td>12.0</td>
<td>18.5</td>
</tr>
<tr>
<td>Cheng</td>
<td>Kunming I</td>
<td>71</td>
<td>31.0</td>
<td>6.1</td>
<td>26.8</td>
<td>10.4</td>
<td>50.0</td>
<td>16.7</td>
</tr>
<tr>
<td></td>
<td>Kunming II</td>
<td>68</td>
<td>28.2</td>
<td>6.3</td>
<td>27.2</td>
<td>10.7</td>
<td>89.3</td>
<td>28.6</td>
</tr>
<tr>
<td>Denys</td>
<td>Amsterdam</td>
<td>63</td>
<td>26.6</td>
<td>6.2</td>
<td>18.1</td>
<td>6.9</td>
<td>4.2</td>
<td>41.7</td>
</tr>
<tr>
<td>van den Heuvel</td>
<td>Amsterdam I</td>
<td>0</td>
<td>22.7</td>
<td>6.1</td>
<td>14.4</td>
<td>7.7</td>
<td>22.2</td>
<td>33.3</td>
</tr>
<tr>
<td>Hoexter</td>
<td>São Paulo I</td>
<td>20</td>
<td>27.2</td>
<td>6.1</td>
<td>13.1</td>
<td>7.0</td>
<td>62.0</td>
<td>54.0</td>
</tr>
<tr>
<td>Koch</td>
<td>Munich</td>
<td>60</td>
<td>20.9</td>
<td>6.2</td>
<td>17.0</td>
<td>6.7</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Kwon</td>
<td>Seoul I</td>
<td>24</td>
<td>20.2</td>
<td>6.0</td>
<td>17.4</td>
<td>5.2</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>Seoul II</td>
<td>23</td>
<td>23.9</td>
<td>6.5</td>
<td>18.9</td>
<td>6.6</td>
<td>0.0</td>
<td>2.9</td>
</tr>
<tr>
<td></td>
<td>Seoul III</td>
<td>2</td>
<td>26.5</td>
<td>6.5</td>
<td>19.0</td>
<td>6.4</td>
<td>1.1</td>
<td>2.2</td>
</tr>
<tr>
<td>Mataix-Col∞</td>
<td>Stockholm</td>
<td>41</td>
<td>25.9</td>
<td>7.7</td>
<td>18.4</td>
<td>9.2</td>
<td>27.3</td>
<td>34.1</td>
</tr>
<tr>
<td>Menchon</td>
<td>Barcelona</td>
<td>97</td>
<td>25.5</td>
<td>5.8</td>
<td>21.4</td>
<td>8.5</td>
<td>20.5</td>
<td>18.8</td>
</tr>
<tr>
<td>Nakamae</td>
<td>Kyoto I</td>
<td>49</td>
<td>25.2</td>
<td>6.4</td>
<td>25.1</td>
<td>9.4</td>
<td>9.8</td>
<td>22.0</td>
</tr>
<tr>
<td></td>
<td>Kyoto II</td>
<td>0</td>
<td>22.4</td>
<td>6.9</td>
<td>25.2</td>
<td>9.1</td>
<td>8.8</td>
<td>20.6</td>
</tr>
<tr>
<td>Nakao</td>
<td>Fukuoka</td>
<td>88</td>
<td>22.5</td>
<td>5.6</td>
<td>24.6</td>
<td>9.5</td>
<td>—</td>
<td>35.8</td>
</tr>
<tr>
<td>Reddy</td>
<td>Bangalore I</td>
<td>0</td>
<td>25.8</td>
<td>7.3</td>
<td>21.7</td>
<td>7.5</td>
<td>15.9</td>
<td>18.2</td>
</tr>
<tr>
<td></td>
<td>Bangalore II</td>
<td>40</td>
<td>25.8</td>
<td>6.3</td>
<td>22.0</td>
<td>7.6</td>
<td>7.7</td>
<td>15.4</td>
</tr>
<tr>
<td>Simpson</td>
<td>New York</td>
<td>0</td>
<td>25.5</td>
<td>3.7</td>
<td>15.0</td>
<td>7.0</td>
<td>21.2</td>
<td>30.3</td>
</tr>
<tr>
<td>Spalletta</td>
<td>Rome</td>
<td>88</td>
<td>23.4</td>
<td>8.9</td>
<td>18.9</td>
<td>10.9</td>
<td>9.5</td>
<td>9.5</td>
</tr>
<tr>
<td>Stein</td>
<td>Cape Town</td>
<td>41</td>
<td>22.9</td>
<td>4.2</td>
<td>13.6</td>
<td>6.6</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Tolin</td>
<td>Connecticut</td>
<td>78</td>
<td>22.7</td>
<td>4.8</td>
<td>—</td>
<td>—</td>
<td>44.4</td>
<td>40.7</td>
</tr>
<tr>
<td>Walitza</td>
<td>Zurich I</td>
<td>59</td>
<td>17.1</td>
<td>9.9</td>
<td>16.7</td>
<td>7.8</td>
<td>47.1</td>
<td>47.1</td>
</tr>
<tr>
<td></td>
<td>Zurich II</td>
<td>56</td>
<td>14.7</td>
<td>1.0</td>
<td>11.1</td>
<td>2.2</td>
<td>50.0</td>
<td>6.3</td>
</tr>
</tbody>
</table>

\(^a\) YBOCS=Yale-Brown Obsessive Compulsive Scale.
investigated using this regression model. Results were considered significant if they exceeded the Bonferroni-corrected p value threshold $5.6 \times 10^{-3}$.

## RESULTS

We included data from 25 adult cohorts and 10 pediatric cohorts. The adult meta- and mega-analyses contained 1,495 OCD patients and 1,472 controls, and the pediatric meta- and mega-analyses contained 335 OCD patients and 287 controls. An overview of the cohorts is provided in Tables 1 and 2. The Supplementary Methods section in the data supplement describes which sites were included in the analyses of clinical characteristics, and what was considered a sufficient amount of data.

### Meta-Analysis

**OCD patients versus healthy controls.**

**Adult comparison:** The results from the analysis comparing all adult OCD patients (N=1,495) with all adult controls (N=1,472) across volumes of nine regions of interest are summarized in Figure 1A and Table 3. Compared with controls, adult OCD patients had significantly smaller hippocampal volumes (Cohen’s $d=-0.13$, 95% CI $=-0.23, -0.04$; $p=5.08 \times 10^{-3}$, % difference $=-2.80$) and larger pallidum volumes ($d=0.16$, 95% CI $=0.06, 0.26$; $p=1.60 \times 10^{-3}$, 

---

**FIGURE 1.** Effect Sizes for Differences in Subcortical Brain Volumes Between Adult Patients With Obsessive-Compulsive Disorder (OCD) and Healthy Control Subjects and Between Unmedicated Pediatric OCD Patients and Pediatric Healthy Control Subjects

A. Subcortical Volume Differences in OCD Patients Compared With Control Subjects

B. Subcortical Volume Differences in Unmedicated Pediatric OCD Patients Compared With Pediatric Healthy Control Subjects

---

*Effect sizes were corrected for age, sex, and intracranial volume. Error bars indicate 95% confidence interval.

Significant effect, $p<5.6 \times 10^{-3}$. *
% difference=3.16). No significant diagnosis-by-sex or diagnosis-by-age interaction effect was observed for any of the subcortical volumes.

**Pediatric comparison:** None of the subcortical volumes were significantly different between pediatric OCD cases (N=335) and controls (N=287) after Bonferroni correction (see Table S2 in the data supplement).

**Influence of medication on subcortical volume.**

**Adult comparisons:** Compared with controls, medicated OCD patients (N=654) had larger lateral ventricles (d=0.24, 95% CI=0.08, 0.41; p=2.95×10^-3, % difference=3.16) and larger pallidum volumes (d=0.29, 95% CI=0.14, 0.44; p=6.43×10^-4, % difference=3.41) as well as smaller hippocampal volumes (d=0.19, 95% CI=0.09, 0.29; p=1.56×10^-4, % difference=3.78) and smaller thalamic volumes (d=0.16, 95% CI=0.16, 0.26; p=1.04×10^-3, % difference=3.28). No significant subcortical volume differences were observed between OCD patients with and without a comorbid lifetime diagnosis of depression.

**Pediatric comparisons:** Too few pediatric samples had sufficient numbers of subjects with major depressive disorder to permit analyses (see the Supplementary Methods section of the data supplement).
Influence of a comorbid anxiety disorder on subcortical volume.

Adult comparisons: Compared with controls, patients without a comorbid anxiety diagnosis (N=1,002) had larger pallidum volumes (d=0.17, 95% CI=0.05, 0.28; p=4.70×10^-3, % difference=2.83) and smaller hippocampal volumes (d=−0.20, 95% CI=−0.30, −0.10; p=1.51×10^-4, % difference=−3.79). We did not detect any significant differences between OCD patients with a comorbid anxiety diagnosis (N=291) and controls. The comparison between OCD patients with and without a comorbid anxiety diagnosis showed that OCD patients with a comorbid lifetime anxiety diagnosis had larger intracranial volumes (d=0.41, 95% CI=0.12, 0.70; p=5.08×10^-3, % difference=2.80) (see Table S6A-C in the data supplement).

Pediatric comparisons: Too few pediatric samples had sufficient numbers of subjects with comorbid anxiety disorders to permit analyses (see the Supplementary Methods section of the data supplement).

Influence of symptom dimensions on subcortical volume.

Adult comparisons: Regression analyses within OCD patients on symptom dimensions (N=1,151) showed no association of the presence of a particular symptom dimension and volume of any of the subcortical structures. 

Pediatric comparisons: Insufficient data on the symptom dimensions were available to perform meta-analyses (see Supplementary Methods in the data supplement).

Influence of age at onset and illness duration on subcortical volume. Stratified analyses (see Table S7A-C in the data supplement) showed that adult OCD patients with an early illness onset (N=626) exhibited larger pallidum volumes (d=0.25, 95% CI=0.12, 0.38; p=2.30×10^-4, % difference=3.68) and that patients with a late illness onset (N=794) exhibited smaller hippocampal volumes (d=−0.18, 95% CI=−0.29, −0.08; p=7.87×10^-4, % difference=−3.36) than controls. No significant differences in subcortical brain volume were found when comparing early-onset with late-onset adult OCD patients. In addition, we did not observe any significant association between age at onset or illness duration (as continuous variables) and subcortical volumes in the adult (N=1,420) or pediatric (N=285) OCD groups (see Tables S8A,B and S9A,B in the data supplement).

Association of illness severity with subcortical volumes. We did not detect any significant associations, in either the adult (N=1,455) or the pediatric (N=328) OCD patients, between illness severity and subcortical volumes (see Tables S10 and S11 in the data supplement).

Moderator analyses. The mean age of each sample and scanner field strength did not moderate case-control differences in subcortical volumes in the adult or pediatric meta-analyses. The percentage of patients using a selective serotonin reuptake inhibitor or an antipsychotic medication in each adult sample did not moderate the subcortical volume differences (see Tables S12 and S13 in the data supplement).

Mega-Analysis

Adult OCD. The results of the adult mega-analysis are summarized in Table S14 in the data supplement. Overall, the mega-analysis yielded results similar to those of the meta-analysis. The case-control mega-analysis indicated larger pallidum volumes (β=0.06; p=1.02×10^-4) and smaller hippocampal volumes (β=−0.05; p=4.66×10^-4). The pallidum (β=0.09; p=5.50×10^-7) and hippocampus (β=−0.09; p=1.99×10^-7) effects were more pronounced in the comparison between medicated OCD patients and controls. Early-onset patients had larger pallidum volumes (β=0.08; p=8.42×10^-6) than controls. Patients with a late illness onset (β=−0.06; p=8.23×10^-5) and patients with comorbid depression (β=−0.07; p=2.75×10^-4) had smaller hippocampal volumes compared with controls.

Pediatric OCD. The results of the pediatric mega-analysis are summarized in Table S18 in the data supplement. Pediatric OCD patients, compared with controls, had larger thalamus volumes (β=0.08; p=5.47×10^-3). The thalamic effect was more pronounced in patients without a comorbid anxiety disorder (β=0.11; p=9.60×10^-4) and in patients without comorbid depression (β=0.09; p=2.16×10^-3).

DISCUSSION

This worldwide collaborative analysis identified distinct subcortical volume alterations in pediatric and adult OCD. The adult meta- and mega-analyses were consistent, and the results showed that, compared with controls, adult OCD patients had significantly smaller hippocampal and larger pallidum volumes. Both findings were more pronounced in the subsample of medicated OCD patients compared with controls. Furthermore, the smaller hippocampal volume seemed to be driven, at least partly, by the OCD patients with comorbid depression and a late illness onset. Indeed, jackknife resampling showed a robust pallidum effect and a hippocampal effect dependent on site characteristics (data not shown). The larger pallidum finding was more pronounced in the adult OCD patients with an early illness onset. The pediatric mega-analysis showed larger thalamus volumes in OCD based on the main group comparison, whereas the meta-analysis showed this only in unmedicated pediatric OCD patients compared with controls. The pediatric mega-analysis also suggests that larger thalamic volumes in pediatric OCD patients is specific to those without comorbid anxiety or depression. The finding of larger thalamic volumes in pediatric OCD is in line with some previous research in pediatric OCD patients (18, 26). Notably, Gilbert et al. (18) suggested a normalizing effect of pharmacological treatment on thalamic volume in pediatric OCD. Our adult meta- and mega-analyses did not reveal group differences in thalamic volume, consistent with the most recent meta-analyses of
SUBCORTICAL VOLUME ALTERATIONS IN PEDIATRIC AND ADULT OCD

OCD (11–13). The only meta-analytic findings of thalamic enlargement in OCD included pediatric patients (14, 19). Our results provide evidence of a clear distinction in thalamic volume across pediatric and adult OCD, and they suggest that an increased thalamic volume may be an early marker of the disease, unrelated to illness severity, and may be related to altered neurodevelopment. Indeed, patients with other neurodevelopmental disorders, such as Tourette’s syndrome (27) and ADHD (28), have also been shown to have a morphologically enlarged thalamus.

Most previous research (11, 13–15, 19) did not report volumetric differences in the hippocampal complex of OCD patients. The (para)hippocampal regions are specifically vulnerable to stress-related toxic changes (29). Greater volume loss in these regions may thus be related to chronic stress and the exaggerated emotional responsiveness seen in OCD (30). The hippocampal effect in OCD patients was more pronounced in medicated patients and seemed to be driven, at least partly, by the OCD patients with comorbid major depression (31). These two findings are probably not independent, since patients with comorbidities are often the patients who receive medication. Furthermore, Selles et al. (32) showed that comorbid depression is associated with a late onset of OCD. This is in line with our finding that the hippocampal effect seemed to be driven by late-onset OCD patients. Other ENIGMA disease working groups, such as those focusing on major depression (33), schizophrenia (34), and bipolar disorder (35), have also observed smaller hippocampal volumes in patients, which suggests that the hippocampal abnormalities in OCD are disease nonspecific and possibly related to chronic stress and comorbid depression.

Our results suggest a key role for the pallidum in adult OCD patients. Previous meta-analyses have reported greater lenticular (i.e., putamen and pallidum) volume in OCD patients (11–14) but decreased lenticular nucleus volume in patients with other anxiety disorders (13). Since repetitive behaviors differentiate OCD from other anxiety disorders, the increased lenticular volume in OCD may reflect these unique symptoms (13). Our analyses also suggest that the early-onset adult OCD patients drive the pallidum effect. We therefore hypothesize that a larger pallidum in OCD patients could be the consequence of illness chronicity. Notably, the ENIGMA Schizophrenia Working Group (34) also observed a larger pallidum in schizophrenia patients compared with controls. Future ENIGMA research will enable cross-diagnosis analyses to further investigate common and distinct neural substrates across psychiatric disease groups.

Our analyses could not replicate the findings of increased putamen and caudate nucleus volumes that have been reported in smaller meta-analyses (11–14). Note that these studies used different segmentation techniques. It is possible that the technique influences findings in cases of adjacent structures such as the pallidum and putamen (36). Our current observations suggest that subcortical alterations in adult OCD may be limited to the pallidum and hippocampus rather than being widespread.

This study constitutes the largest meta- and mega-analyses of subcortical brain volumes in OCD to date. Strengths of this study include the sample size (N=3,589) and inclusion of both adults and children. Another strength is our strategy of ensuring methodological homogeneity by standardizing brain segmentation techniques and statistical models across all participating samples, which increased the power to detect small effects. A similar strategy has been used in parallel by other ENIGMA working groups (33–35). This method generates highly significant findings and allows us to systematically investigate the effects of clinical characteristics on brain alterations in OCD patients.

This study also had limitations. First, the individual sites in our study varied in workstation vendor and operating system version, which have been shown to have effects on estimates of brain volume and cortical thickness (37). Additionally, Schoemaker et al. (38) showed that FreeSurfer tends to overestimate subcortical volumes in children. However, this nonsystematic error probably affects patients and controls equally. Second, although we have pooled an enormous amount of data, subjects with comorbidities and subjects categorized to each specific symptom dimension, especially in the pediatric data sets, were still limited. However, the key variable—the Children’s YBOCS score, the gold-standard clinical instrument in pediatric OCD research—was available for all subjects. Third, the structure labeled as “thalamus” by FreeSurfer’s segmentation algorithm may contain both white matter and gray matter. We therefore cannot conclude that thalamic enlargement involves solely gray matter enlargement. Fourth, our findings indicate medication effects. It should be noted, however, that only current medication status was taken into consideration. It is difficult to attribute the results to direct effects of the medication itself. Furthermore, the range of medications that are generally prescribed for OCD patients is broad. Although we tested whether different types of medication influenced our findings, we were not able to calculate relative dosages of different medication types and analyze medication effects in a more fine-grained manner because of the retrospective nature of our study. Thus, we need to interpret these findings with caution.

Despite these limitations, the results of this first initiative of the ENIGMA OCD Working Group clearly indicate a key role of the thalamus and the pallidum in the pathophysiology of pediatric and adult OCD, respectively. Our findings suggest a different pattern of subcortical abnormalities in pediatric and adult OCD patients, which is in line with the developmental nature of OCD and neuroplastic changes during the course of the illness. The present study is a first step toward identifying robust brain volume alterations in OCD patients. An important next step is to apply similar methods in order to identify robust cortical imaging markers on cortical thickness and surface area measures associated with OCD.
AUTHOR AND ARTICLE INFORMATION

From the Department of Psychiatry and the Department of Anatomy and Neurosciences, VU University Medical Center, Amsterdam; Neuroscience Campus Amsterdam, Free University/VU University Medical Center, Amsterdam; the Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; the Centre for Addiction and Mental Health and Hospital for Sick Children, Toronto; the Mathison Centre for Mental Health Research and Education, Cumming School of Medicine, University of Calgary, Calgary, Canada; the Department of Psychiatry, Institute of Psychiatry, University of São Paulo School of Medicine, São Paulo, Brazil; Clinical Research Group Psychiatry and Clinical Psychobiology, Division of Neuroscience, Scientific Institute Ospedale San Raffaele, Milan; the Department of Psychology, Humboldt-Universität zu Berlin, Berlin; the Obsessive–Compulsive Disorder Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India; the Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich; Magnetic Resonance Image Core Facility, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; the Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, China; the Department of Brain and Cognitive Sciences, University of Michigan, Ann Arbor; the Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam; the Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam; the Department of Psychiatry, University of Michigan, Ann Arbor; the Department of Psychiatry, University of Cape Town, Cape Town, South Africa; the Department of Psychiatry, University of Stellenbosch, Cape Town; the Department of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute—IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona; the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.; the Imaging Genetics Center, Mark and Mary Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Marina del Rey, De Bascule, Academic Center for Child and Adolescent Psychiatry, Amsterdam; the Department of Child and Adolescent Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam; the Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; the Department of Neuropediatrics, Klinikum rechts der Isar, Technische Universität München, Munich; TUM-Neuroimaging Center (TUM-NIC) of Klinikum rechts der Isar, Technische Universität München, Munich; the Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea; the Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic Universitari, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; the Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain; SU/UCT MRC Unit on Anxiety and Stress Disorders, Department of Psychiatry, University of Stellenbosch, Cape Town, South Africa; Columbia University Medical Center, New York; the Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute and Columbia University, New York; the Department of Clinical Neurosciences, Center for Psychiatric Research and Education, Karolinska Institutet, Stockholm; the Department of Clinical Sciences, University of Barcelona, Barcelona, Spain; the Mood Disorders Clinic and the Anxiety Treatment and Research Center, St. Joseph’s HealthCare, Hamilton, Canada; the Department of Neural Computation for Decision Making, ATR Brain Information Communication Research Laboratory Group, Kyoto, Japan; the Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome; the Center of Mathematics, Computation, and Cognition, Universidade Federal Do ABC, Santo Andre, Brazil; the Center for OCD and Related Disorders, New York State Psychiatric Institute, New York; the Department of Psychology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain; the Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston; the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.; the Clinical Neuro- science and Development Laboratory, Olin Neuropsychiatry Research Center, Hartford, Conn.; the Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; the James J. Peters VA Medical Center, Bronx, New York; the Institute of Living/Hartford Hospital, Hartford, Conn.; the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; the Shanghai Key Laboratory of Psychotic Disorders, Shanghai; and the Department of Internal Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China. Address correspondence to Ms. Boedhoe (p.boedhoe@vumc.nl).

See the online data supplement for the complete list of ENIGMA OCD Working Group members.

Presented in part at the 11th Scientific Meeting of the International College of Obsessive Compulsive Spectrum Disorders (ICOCOS), Amsterdam, Sept. 2, 2015.

The ENIGMA OCD Working Group gratefully acknowledges support from the NIH BD2K award U54 EB020403-02 (principal investigator, Dr. Thompson). Supported by the Neuroscience Campus Amsterdam, IPB-grant to Dr. Schmaal and Dr. van den Heuvel; the Hartmann Muller Foundation (No. 1460 to Dr. Brem); the International Obsessive-Compulsive Disorder Foundation Research Award to Dr. Groner; the Deutsche Forschungsgemeinschaft (KO 3744/2-1 to Dr. Koch); the Marató TV3 Foundation grants 01/2010 and 091710 to Dr. Lazaro; the Wellcome Trust and a pump priming grant from the South London and Maudsley Trust, London (project grant no. 064846) to Dr. Mataix-Cols; the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT KAKENHI No. 26461753 to Dr. Nakamae); Government of India grants to Prof. Reddy (SR/50/HS/0016/2011) and Dr. Narayanaswamy ( DST INSPIRE faculty grant -IIFA2-LSBM-26) of the Department of Science and Technology; the Government of India grants to Prof. Reddy (No. BT/PR13334/Med/30/259/2009) and Dr. Narayanaswamy (BT/06/114Y/2012) of the Department of Biotechnology; the Wellcome–DBT India Alliance grant to Dr. Venkatasubramanian (500236/2/11/Z); the Carlos III Health Institute (CP10/00604, PI13/00918, PI13/01958, PI04/2013, PI040829); FEDER funds/European Regional Development Fund, AGAUR (2014 SGR 1672 and 2014 SGR 489); a “Miguel Servet” contract (CP10/00604) from the Carlos III Health Institute to Dr. Soriano-Mas; the Italian Ministry of Health (RC10-11-12-13-14-15A to Dr. Spalletta); the Swiss National Science Foundation (No. 320030_130237 to Dr. Wältizta); and the Netherlands Organization for Scientific Research (NWO VIDI 917-15-318 to Dr. van Wingen).

The authors acknowledge Juliane Ball, Ph.D., Elizabeth Buimer, B.Sc., Kenji Fukui, M.D., Ph.D., Jin Narumoto, M.D., Ph.D., Seiji Nishida, M.D., Ph.D., Reto Iannaccone, Ph.D., Yuki Sakai, M.D., Ph.D., Tobias U. Hauser, Ph.D., Anri Watanabe, M.D., and Kei Yamada, M.D., Ph.D.

Dr. Menchon has received grants and served as consultant, adviser, or speaker for AB-Biotics, Ferrer, GlaxoSmithKline, Janssen, Lundbeck, Medtronic, Otsuka, and the Spanish Ministry of Science and Innovation (CIBERSAM). Dr. Minuzzi has received grant or research support from the Alternative Funding Plan Innovation Fund, the Brain and Behavioral Foundation, the Canadian Institutes of Health Research, the Hamilton Health Sciences Foundation, the Ontario Brain Institute, and the Ontario Mental Health Foundation; he has served as a consultant or speaker for Bristol–Myers Squibb, the Canadian Psychiatric Association, the Canadian Network for Mood and Anxiety Treatments, and Lundbeck. Dr. Simpson receives royalties from Cambridge University Press and UpToDate. Prof. Dr. Wältzta has received lecture honoraria from Ophopharma and Eli Lilly; her work and research have been partially supported by the Swiss National Science Foundation, the German Research Foundation, Hochspezialisierte Medizin of the Canton of Zurich, and the German Federal Ministry of Education and Research. Dr. Stein has received research grants or consultancy honoraria from AMBRF, Biocodex, Cipla, Lundbeck, the National Responsible Gambling Foundation, Novartis,
REFERENCES


